Our study shows that ALK1-dependent LDL entry into the endothelium is a critical step for apoB entrapment in the vessel wall and provides a therapeutic rationale to block LDL entry into the endothelium as a mechanism to treat the vessel wall and alter the course of ASCVD. The gene discussed is APOB; the disease is atherosclerosis.